In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the continued growth of its NETHERTON NOW awareness campaign, which has generated nearly 2 million video views and more than 24 million impressions globally. Launched in February 2025, the campaign aims to amplify the voices of patients, caregivers, and clinicians affected by Netherton Syndrome, a rare genetic skin disorder caused by mutations in the SPINK5 gene. The condition leads to excessive skin shedding, chronic inflammation, recurrent infections, and can be life-threatening, with an estimated 10-20% of newborns not surviving. Those who survive often face lifelong complications and severe pain.
Rare Disease Day, established in 2008 by EURORDIS and observed annually on the last day of February, raises awareness for rare conditions that collectively impact hundreds of millions worldwide. NETHERTON NOW has released a new video titled "If There Was a Cure," featuring patients and families reflecting on what meaningful treatment progress would mean. The video is available at https://youtu.be/AIcGZQEumF0?si=5d226QrYKR3m-hHC.
Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, stated, "When we launched NETHERTON NOW, we hoped it would resonate, but the response has far surpassed anything we anticipated. Individuals who had previously lived in silence now have a platform to share their stories and connect with one another." Dr. Michael Myers, CEO, emphasized the company's responsibility to advance rigorous clinical research and ensure access to potential treatments. Quoin's lead investigational candidate, QRX003, is currently in late-stage pivotal clinical trials for Netherton Syndrome.
The growing awareness underscores the urgent need for approved therapies. For more information about Rare Disease Day, visit www.rarediseaseday.org. To learn more about Netherton Syndrome and the NETHERTON NOW campaign, visit https://nethertonnow.com.
